Sutro Biopharma (NASDAQ:STRO) Rating Increased to Strong-Buy at Truist Financial

Truist Financial upgraded shares of Sutro Biopharma (NASDAQ:STRO) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Citizens Jmp upped their price objective on shares of Sutro Biopharma from $35.00 to $41.00 and gave the company a “market outperform” rating in a research report on Thursday, April 23rd. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $8.00 to $27.00 in a research report on Tuesday, March 24th. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and upped their price objective for the company from $10.00 to $28.00 in a research report on Tuesday, March 24th. Finally, Leerink Partners assumed coverage on shares of Sutro Biopharma in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $38.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.78.

Sutro Biopharma Stock Down 2.8%

Shares of NASDAQ STRO opened at $37.32 on Monday. Sutro Biopharma has a 52-week low of $6.74 and a 52-week high of $39.74. The firm has a fifty day moving average of $26.11 and a 200-day moving average of $16.72. The stock has a market capitalization of $618.39 million, a PE ratio of -1.43 and a beta of 1.63.

Institutional Investors Weigh In On Sutro Biopharma

A number of institutional investors have recently modified their holdings of STRO. Bridgeway Capital Management LLC raised its stake in shares of Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after purchasing an additional 66,372 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Sutro Biopharma in the 2nd quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury acquired a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $86,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma News Summary

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Truist Financial upgraded Sutro to a “Strong-Buy,” a near?term positive catalyst that can attract buyer interest and support the share price. Zacks: Truist Upgrade
• Positive Sentiment: Lifesci Capital published extensive multi?year EPS models and also rates STRO “Strong?Buy.” Their projections show improving (less negative) losses over time versus the consensus, which helps justify the bullish analyst stance and may underpin investor confidence in the company’s trajectory. MarketBeat: Lifesci Capital Estimates
• Negative Sentiment: Despite the bullish ratings, Lifesci’s forecasts still show substantial multi?year losses (examples: FY2026 ? ($6.60), FY2027 ? ($5.45), FY2030 ? ($6.31)), a reminder that Sutro remains unprofitable and exposed to execution and financing risk — a factor that can limit upside and contribute to short?term selling or volatility. MarketBeat: Lifesci Capital Estimates (details)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.